Advertisement
In Australia

Cancers Differ in Indigenous, Non-Indigenous Populations

0
Generally, indigenous cancer rates lower, except for lung cancer in men, cervical in women
Hypofractionated radiation therapy with incorporated boost over a shorter period of time treats early-stage breast cancer as well as longer

ASTRO: Shorter Radiation OK for Early Breast Cancers

0
High-dose therapy shows same survival rates as longer course of standard radiation
Cardiac surgery patients given blood stored for more than six weeks face no greater harm than those who get blood donated within two weeks

Older Blood Appears Safe for Cardiac Surgery Patients

0
Storage duration doesn't affect complications, mortality rate
Coagadex (coagulation Factor X) has been approved by the U.S. Food and Drug Administration as the first coagulation factor replacement therapy for people with a rare blood disorder known as hereditary Factor X deficiency.

FDA Approves Coagadex for Rare Clotting Disorder

0
First coagulation therapy sanctioned for Factor X deficiency
For patients with metastatic squamous non-small-cell lung cancer

Report Details Benefits, Risks of Nivolumab for Squamous NSCLC

0
Benefit-risk summary shows beneficial effects for patients with metastatic SQ NSCLC
For patients with colorectal cancer

SNORA42 Identified as Novel Oncogene in Colorectal Cancer

0
Increased SNORA42 expression is independent prognostic factor for overall, disease-free survival
Markets with greater increases in physician-hospital integration show greater increases in spending for outpatient care

Outpatient Spending Higher With Physician-Hospital Integration

0
Authors say increased spending attributable to price increases, not utilization changes
The American Cancer Society is delaying the recommended age when a woman should start receiving annual mammograms

ACS: Annual Mammograms Should Start at Age 45

0
Previous recommendation was 40; new guidelines place greater emphasis on approach of menopause
Men's health supplements offer no benefit for patients with localized prostate cancer

ASTRO: Men’s Health Supplements No Use in Prostate CA

0
No reduction in risk of distant metastasis, cancer-related deaths, radiation-linked adverse effects
Praxbind (idarucizumab) has been approved for use in patients who are taking the anticoagulant Pradaxa (dabigatran) when there is an urgent need to reverse Pradaxa's anticoagulant effects

FDA Approves Praxbind to Reverse Pradaxa’s Effect

0
Praxbind cleared for emergency use with Pradaxa when bleeding can't be controlled